Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors - Ma, Yu-Xiang; Liu, Fu-Rong; Zhang, Yang; Chen, Qun; Chen, Zhi-Qiang; Liu, Qian-Wen; Huang, Yan; Yang, Yun-Peng; Fang, Wen-Feng; Xi, Ning; Kang, Ning; Zhuang, Yu-Lei; et al. (Frontiers in immunology, 2022)
Keywords: Administration, Oral; Adult; AXL; c-Mer Tyrosine Kinase; Humans; Immunology; Maximum Tolerated Dose; MET; Neoplasms - pathology; phase I; preclinical; Protein Kinase Inhibitors - therapeutic use; tyrosine kinase inhibitor; VEGFR2; VEGFR2; phase I; tyrosine kinase inhibitor; AXL; preclinical; MET